Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Furazidin is a nitrofuran derivative antibacterial agent with bacteriostatic action. It is active against both gram-positive and gram-negative bacteria and is primarily used for the treatment of urinary tract infections (UTIs), as well as skin and soft tissue infections. Its mechanism of action involves the reduction by bacterial enzymes to reactive intermediates that damage bacterial DNA and other macromolecules such as ribosomal proteins and enzymes involved in metabolism. This broad mechanism disrupts multiple cellular processes within bacteria[1][4]. Resistance development is rare due to its multi-targeted effects. It has been marketed under various brand names in Eastern Europe and some Asian countries[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on furazidin.